Research Questions/Hypotheses
Are there any correlations of azole antifungals and infections post-transplant / antifungal
resistances and levels of immunosuppressive drugs? (ii) Is there any azole-content in the 'native' donor and donor organ
respectively? (iii) Is there any pre-existing azole content of the potential organ transplant recipient? (iv) Does the pre-existing
azole content ofthe deceased organ donor correlate with donor demographics and laboratory parameters? (v) Does the pre-existing
azole content ofthe organ recipient correlate with recipient demographics and laboratory parameters? (vi) Does the pre-existing
azole content of donor organ and/or recipient interfere with the outcome (graft and patient survival) after solid organ
transplantation?
Approach/Methods
The clinical trial will be performed on liver transplant patients (n = 60), including patients who received a
liver after normothermic perfusion, and kidney transplant patients (n = 80). For deceased donor livers and kidneys, surrounding
fatty tissue will be sampled to undergo measurement of azole content. For liver transplant patients, an additional needle biopsy
will be taken during the benching procedure, before the implanting or normothermic perfusion process is started. The fatty tissue
and the liver biopsy will be snap frozen and stored at -80°C until further use.
